148 related articles for article (PubMed ID: 32534450)
1. Aberrantly glycosylated integrin α3β1 is a unique urinary biomarker for the diagnosis of bladder cancer.
Jin D; Zhang R; Chen H; Li C
Aging (Albany NY); 2020 Jun; 12(11):10844-10862. PubMed ID: 32534450
[TBL] [Abstract][Full Text] [Related]
2. A comparison of urinary nuclear matrix protein-22 and bladder tumour antigen tests with voided urinary cytology in detecting and following bladder cancer: the prognostic value of false-positive results.
Poulakis V; Witzsch U; De Vries R; Altmannsberger HM; Manyak MJ; Becht E
BJU Int; 2001 Nov; 88(7):692-701. PubMed ID: 11890239
[TBL] [Abstract][Full Text] [Related]
3. Combined use of epithelial membrane antigen and nuclear matrix protein 52 as sensitive biomarkers for detection of bladder cancer.
Attallah AM; El-Far M; Abdallah SO; El-Waseef AM; Omran MM; Abdelrazek MA; Attallah AA; Saadh MJ; Radwan M; El-waffaey KA; Abol-Enei H
Int J Biol Markers; 2015 Nov; 30(4):e407-13. PubMed ID: 26349665
[TBL] [Abstract][Full Text] [Related]
4. The addition of urinary urokinase-type plasminogen activator to urinary nuclear matrix protein 22 and cytology improves the detection of bladder cancer.
Shariat SF; Casella R; Monoski MA; Sulser T; Gasser TC; Lerner SP
J Urol; 2003 Dec; 170(6 Pt 1):2244-7. PubMed ID: 14634389
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the nuclear matrix protein 22 with voided urine cytology and BTA stat test in the diagnosis of transitional cell carcinoma of the bladder.
Sözen S; Biri H; Sinik Z; Küpeli B; Alkibay T; Bozkirli I
Eur Urol; 1999 Sep; 36(3):225-9. PubMed ID: 10450007
[TBL] [Abstract][Full Text] [Related]
6. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
[TBL] [Abstract][Full Text] [Related]
7. NMP22 in transitional cell carcinoma of the urinary bladder.
Su CK; Yang CR; Horng YY; Kao YL; Ho HC; Ou YC; Cheng CL
J Chin Med Assoc; 2003 May; 66(5):294-8. PubMed ID: 12908572
[TBL] [Abstract][Full Text] [Related]
8. UBE2C cell-free RNA in urine can discriminate between bladder cancer and hematuria.
Kim WT; Jeong P; Yan C; Kim YH; Lee IS; Kang HW; Kim YJ; Lee SC; Kim SJ; Kim YT; Moon SK; Choi YH; Kim IY; Yun SJ; Kim WJ
Oncotarget; 2016 Sep; 7(36):58193-58202. PubMed ID: 27528424
[TBL] [Abstract][Full Text] [Related]
9. Urinary micro-RNA expressions and protein concentrations may differentiate bladder cancer patients from healthy controls.
Güllü Amuran G; Tinay I; Filinte D; Ilgin C; Peker Eyüboğlu I; Akkiprik M
Int Urol Nephrol; 2020 Mar; 52(3):461-468. PubMed ID: 31679136
[TBL] [Abstract][Full Text] [Related]
10. A urinary microRNA (miR) signature for diagnosis of bladder cancer.
Hofbauer SL; de Martino M; Lucca I; Haitel A; Susani M; Shariat SF; Klatte T
Urol Oncol; 2018 Dec; 36(12):531.e1-531.e8. PubMed ID: 30322728
[TBL] [Abstract][Full Text] [Related]
11. Discovery and validation of potential urinary biomarkers for bladder cancer diagnosis using a pseudotargeted GC-MS metabolomics method.
Zhou Y; Song R; Ma C; Zhou L; Liu X; Yin P; Zhang Z; Sun Y; Xu C; Lu X; Xu G
Oncotarget; 2017 Mar; 8(13):20719-20728. PubMed ID: 28157703
[TBL] [Abstract][Full Text] [Related]
12. Identification and validation of AIB1 and EIF5A2 for noninvasive detection of bladder cancer in urine samples.
Zhou BF; Wei JH; Chen ZH; Dong P; Lai YR; Fang Y; Jiang HM; Lu J; Zhou FJ; Xie D; Luo JH; Chen W
Oncotarget; 2016 Jul; 7(27):41703-41714. PubMed ID: 27203388
[TBL] [Abstract][Full Text] [Related]
13. Clinical performance and utility of a NNMT-based urine test for bladder cancer.
Pozzi V; Di Ruscio G; Sartini D; Campagna R; Seta R; Fulvi P; Vici A; Milanese G; Brandoni G; Galosi AB; Montironi R; Cecati M; Emanuelli M
Int J Biol Markers; 2018 Jan; 33(1):94-101. PubMed ID: 29148015
[TBL] [Abstract][Full Text] [Related]
14. Increased accuracy of a novel mRNA-based urine test for bladder cancer surveillance.
Pichler R; Fritz J; Tulchiner G; Klinglmair G; Soleiman A; Horninger W; Klocker H; Heidegger I
BJU Int; 2018 Jan; 121(1):29-37. PubMed ID: 28941000
[TBL] [Abstract][Full Text] [Related]
15. Comparative evaluation of the BTAstat test, NMP22, and voided urine cytology in the detection of primary and recurrent bladder tumors.
Giannopoulos A; Manousakas T; Mitropoulos D; Botsoli-Stergiou E; Constantinides C; Giannopoulou M; Choremi-Papadopoulou H
Urology; 2000 Jun; 55(6):871-5. PubMed ID: 10840098
[TBL] [Abstract][Full Text] [Related]
16. [The role of telomerase activity in non-invasive diagnostics of bladder cancer].
Glybochko PV; Alyaev JG; Potoldykova NV; Polyakovsky KA; Vinarov AZ; Glukhov AI; Gordeev SA
Urologiia; 2016 Aug; (4):76-81. PubMed ID: 28247730
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of urinary level of NMP22 as a diagnostic marker for stage pTa-pT1 bladder cancer: comparison with urinary cytology and BTA test.
Del Nero A; Esposito N; Currò A; Biasoni D; Montanari E; Mangiarotti B; Trinchieri A; Zanetti G; Serrago MP; Pisani E
Eur Urol; 1999 Feb; 35(2):93-7. PubMed ID: 9933801
[TBL] [Abstract][Full Text] [Related]
18. Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment.
Soloway MS; Briggman V; Carpinito GA; Chodak GW; Church PA; Lamm DL; Lange P; Messing E; Pasciak RM; Reservitz GB; Rukstalis DB; Sarosdy MF; Stadler WM; Thiel RP; Hayden CL
J Urol; 1996 Aug; 156(2 Pt 1):363-7. PubMed ID: 8683680
[TBL] [Abstract][Full Text] [Related]
19. Urinary calprotectin: a new diagnostic marker in urothelial carcinoma of the bladder.
Ebbing J; Mathia S; Seibert FS; Pagonas N; Bauer F; Erber B; Günzel K; Kilic E; Kempkensteffen C; Miller K; Bachmann A; Rosenberger C; Zidek W; Westhoff TH
World J Urol; 2014 Dec; 32(6):1485-92. PubMed ID: 24378824
[TBL] [Abstract][Full Text] [Related]
20. MALBAC-based chromosomal imbalance analysis: a novel technique enabling effective non-invasive diagnosis and monitoring of bladder cancer.
Liu H; He W; Wang B; Xu K; Han J; Zheng J; Ren J; Shao L; Bo S; Lu S; Lin T; Huang J
BMC Cancer; 2018 Jun; 18(1):659. PubMed ID: 29907142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
